MedTrace Logo

RAD001 in Patients With Metastatic, Hormone-Refractory Prostate Cancer

NCT00629525 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2015-03-03

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the biochemical response rate (PSA) to single agent RAD001 in patients with metastatic hormone-refractory prostate cancer (HRPC).

Conditions

  • Hormone Refractory Prostate Cancer

Interventions

DRUG

RAD001

RAD001 at a dose of 10 mg PO daily

Sponsors & Collaborators

Principal Investigators

  • Daniel J George, MD · Duke Health

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-08-31
Primary Completion
2009-12-31
Completion
2010-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00629525 on ClinicalTrials.gov